Biggest changeYear Ended December 31, Variance % 2023 2022 Revenue $ 2,602,415 $ 2,406,840 $ 195,575 8 % Expenses: Cost of revenue (exclusive of depreciation and amortization, which are shown separately below) 760,031 743,987 16,044 2 % Operating expenses: Advertising and marketing 688,854 623,536 65,318 10 % Sales 213,780 227,172 (13,392) (6) % Technology and development 348,521 333,629 14,892 4 % General and administrative 464,659 449,855 14,804 3 % Acquisition, integration, and transformation costs 21,110 15,620 5,490 35 % Restructuring costs 16,942 7,416 9,526 128 % Depreciation 11,138 11,407 (269) (2) % Amortization 325,933 244,620 81,313 33 % Goodwill impairment 0 13,402,812 (13,402,812) n/m Total expenses 2,850,968 16,060,054 (13,209,086) (82) % Loss from operations (248,553) (13,653,214) 13,404,661 98 % Interest income (46,782) (12,674) (34,108) 269 % Interest expense 22,282 21,944 338 2 % Other (income) expense, net (4,445) 859 (5,304) n/m Loss before provision for income taxes (219,608) (13,663,343) 13,443,735 98 % Provision for income taxes 760 (3,812) 4,572 120 % Net loss $ (220,368) $ (13,659,531) $ 13,439,163 98 % Net loss per share, basic and diluted $ (1.34) $ (84.60) $ 83.26 98 % EBITDA (1) $ 88,518 $ 5,625 $ 82,893 n/m Adjusted EBITDA (1) $ 328,120 $ 246,513 $ 81,607 33 % ______________________________________ n/m – not meaningful (1) Non-GAAP Financial Measures 63 Table of Contents The following table reconciles net loss, the most directly comparable GAAP measure, to EBITDA and Adjusted EBITDA for the years ended December 31, 2023 and 2022 (in thousands): Year Ended December 31, 2023 2022 Net loss $ (220,368) $ (13,659,531) Add: Goodwill impairment 0 13,402,812 Interest income (46,782) (12,674) Interest expense 22,282 21,944 Other (income) expense, net (4,445) 859 Provision for income taxes 760 (3,812) Depreciation 11,138 11,407 Amortization 325,933 244,620 EBITDA 88,518 5,625 Stock-based compensation 201,550 217,852 Acquisition, integration, and transformation costs 21,110 15,620 Restructuring costs 16,942 7,416 Adjusted EBITDA $ 328,120 $ 246,513 Teladoc Health Integrated Care $ 191,871 $ 135,153 BetterHelp 136,249 114,116 Other 0 (2,756) Adjusted EBITDA $ 328,120 $ 246,513 Revenue.
Biggest changeYear Ended December 31, Variance % 2024 2023 Revenue $ 2,569,574 $ 2,602,415 $ (32,841) (1) % Costs and expenses: Cost of revenue (exclusive of depreciation and amortization, which are shown separately below) 751,270 760,031 (8,761) (1) % Advertising and marketing 705,787 688,854 16,933 2 % Sales 204,993 213,780 (8,787) (4) % Technology and development 307,274 348,521 (41,247) (12) % General and administrative 435,490 464,659 (29,169) (6) % Goodwill impairment 790,000 — 790,000 n/a Acquisition, integration, and transformation costs 1,743 21,110 (19,367) (92) % Restructuring costs 20,355 16,942 3,413 20 % Amortization of intangible assets 363,365 325,933 37,432 11 % Depreciation of property and equipment 10,183 11,138 (955) (9) % Total costs and expenses 3,590,460 2,850,968 739,492 26 % Loss from operations (1,020,886) (248,553) (772,333) n/m Interest income (57,071) (46,782) (10,289) 22 % Interest expense 23,803 22,282 1,521 7 % Other expense (income), net 6,035 (4,445) 10,480 (236) % Loss before provision for income taxes (993,653) (219,608) (774,045) n/m Provision for income taxes 7,592 760 6,832 n/m Net loss $ (1,001,245) $ (220,368) $ (780,877) n/m Net loss per share, basic and diluted $ (5.87) $ (1.34) $ (4.53) n/m Adjusted EBITDA (1) $ 310,711 $ 328,120 $ (17,409) (5) % ______________________________________ n/m – not meaningful (1) Non-GAAP Financial Measures 64 Table of Contents The following table reconciles net loss, the most directly comparable GAAP measure, to Adjusted EBITDA for the years ended December 31, 2024 and 2023 (in thousands): Year Ended December 31, 2024 2023 Net loss $ (1,001,245) $ (220,368) Add: Provision for income taxes 7,592 760 Other expense (income), net 6,035 (4,445) Interest expense 23,803 22,282 Interest income (57,071) (46,782) Depreciation of property and equipment 10,183 11,138 Amortization of intangible assets 363,365 325,933 Restructuring costs 20,355 16,942 Acquisition, integration, and transformation costs 1,743 21,110 Goodwill impairment 790,000 — Stock-based compensation 145,951 201,550 Adjusted EBITDA $ 310,711 $ 328,120 Integrated Care $ 232,902 $ 191,871 BetterHelp 77,809 136,249 Adjusted EBITDA $ 310,711 $ 328,120 Revenue.
Integrated Care Members. U.S. Integrated Care members represent the number of unique individuals who have paid access and visit fee only access to our suite of integrated care services in the U.S. at the end of the applicable period.
Integrated Care members represent the number of unique individuals who have paid access and visit fee only access to our suite of integrated care services in the U.S. at the end of the applicable period.
Sales Expenses Sales expenses consist primarily of employee-related expenses, including salaries, benefits, commissions, and incentive-based awards, employment taxes, travel and stock-based compensation costs for our employees engaged in sales, account management, and sales support in addition to commissions paid to external brokers. Our sales expenses exclude certain allocations of occupancy expense as well as depreciation and amortization.
Sales Expenses Sales expenses consist primarily of employee-related expenses, including salaries, benefits, commissions, incentive-based awards, and stock-based compensation, employment taxes, travel costs for our employees engaged in sales, account management, and sales support in addition to commissions paid to external brokers. Our sales expenses exclude certain allocations of occupancy expense as well as depreciation and amortization.
We may in the future enter into arrangements to acquire or invest in complementary businesses, services, technologies, and intellectual property rights. We may be required to seek additional equity or debt financing to fund working capital, capital expenditures and acquisitions, and to settle debt obligations.
We may in the future enter into arrangements to acquire or invest in additional complementary businesses, services, technologies, and intellectual property rights. We may be required to seek additional equity or debt financing to fund working capital, capital expenditures and acquisitions, and to settle debt obligations.
Cash from Financing Activities Cash provided by financing activities for the year ended December 31, 2023 was $10.9 million and primarily consisted of $1.5 million of proceeds from the exercise of employee stock options and $9.7 million of proceeds from participants in our employee stock purchase plan.
Cash provided by financing activities for the year ended December 31, 2023 was $10.9 million and primarily consisted of $1.5 million of proceeds from the exercise of employee stock options and $9.7 million of proceeds from participants in our employee stock purchase plan.
We further believe that these financial measures are useful financial metrics to assess our operating performance and financial and business trends from period-to-period by excluding certain items that we believe are not representative of our core business, and that free cash flow reflects an additional way of viewing our liquidity that, when viewed together with GAAP results, provides management, investors, and other users of our financial information with a more complete understanding of factors and trends affecting our cash flows.
We further believe that these financial measures are useful to assess our operating performance and financial and business trends from period-to-period by excluding certain items that we believe are not representative of our core business, and that free cash flow reflects an additional way of viewing our liquidity that, when viewed together with GAAP results, provides management, investors, and other users of our financial information with a more complete understanding of factors and trends affecting our cash flows.
In combination with the expansion of our capabilities, we believe that these trends present significant opportunities for virtual healthcare to address the most pressing, universal healthcare challenges through trusted solutions, such as ours, that deliver convenient, affordable, and high-quality care; empower individuals to manage and improve their health; and enable providers to offer their best care for their patients.
In combination with the expansion of our capabilities, we believe that these trends continue to present significant opportunities for virtual healthcare to address the most pressing, universal healthcare challenges through trusted solutions, such as ours, that deliver convenient, affordable, and high-quality care; empower individuals to manage and improve their health; and enable providers to offer their best care for their patients.
EBITDA, Adjusted EBITDA, and Free Cash Flow To supplement our financial information presented in accordance with U.S. generally accepted accounting principles (“GAAP”), we use non-GAAP financial measures to clarify and enhance an understanding of past performance, which include EBITDA (as defined below), Adjusted EBITDA, and free cash flow.
Adjusted EBITDA, and Free Cash Flow To supplement our financial information presented in accordance with U.S. generally accepted accounting principles (“GAAP”), we use certain non-GAAP financial measures to clarify and enhance an understanding of past performance, which include Adjusted EBITDA (as defined below) and free cash flow.
The research and development expenses may enable future revenue growth but are not directly related to current revenues. 59 Table of Contents Technology and development expenses include personnel and related expenses (including salaries and benefits, incentive compensation, and stock-based compensation) for software engineering, information technology infrastructure, security and compliance, product development, and support for our efforts to add new features and ensure the reliability or scalability of our existing solutions.
The research and development expenses may enable future revenue growth but are not directly related to current revenues. 61 Table of Contents Technology and development expenses include personnel and related expenses (including salaries and benefits, incentive compensation, and stock-based compensation) for software engineering, information technology infrastructure, security and compliance, product development, and support for our efforts to add new features and ensure the reliability or scalability of our existing solutions.
This principle is achieved through applying the following five-step approach: • Identification of the contract, or contracts, with a Client. 55 Table of Contents • Identification of the performance obligations in the contract. • Determination of the transaction price. • Allocation of the transaction price to the performance obligations in the contract. • Recognition of revenue when, or as, we satisfy a performance obligation.
This principle is achieved through applying the following five-step approach: • Identification of the contract, or contracts, with a Client. • Identification of the performance obligations in the contract. 57 Table of Contents • Determination of the transaction price. • Allocation of the transaction price to the performance obligations in the contract. • Recognition of revenue when, or as, we satisfy a performance obligation.
In the event that additional financing is required from outside sources, we may not be able to raise it on terms acceptable to us or at all, which would adversely affect our business, financial condition and results of operations. Historically, we have financed our operations primarily through sales of equity securities, debt issuance, and bank borrowings. See Note 10.
In the event that additional financing is required from outside sources, we may not be able to raise it on terms acceptable to us or at all, which would adversely affect our business, financial condition, and results of operations. Historically, we have financed our operations primarily through sales of equity securities, debt issuance, and bank borrowings.
Today, we have a vision of making virtual care the first step on any healthcare journey, and we are delivering on this mission by providing whole person virtual care that includes primary care, mental health, chronic condition management, and more.
Today, we have a vision of making virtual care the first step on any healthcare journey, and we are delivering on this mission by providing virtual care that includes primary care, mental health, chronic condition management, and more.
Our revenue growth rate and long-term profitability are affected by our ability to increase cross selling capability among our existing members over time because we derive a substantial portion of our revenue from access and other fees via Client contracts that provide members access to our professional provider network in exchange for a contractual based periodic fee.
Our revenue growth rate and long-term profitability are affected by our ability to increase cross selling capability among our existing members over time because we derive a substantial portion of our revenue from access and other fees via Client contracts that provide members access to the THMG Association professional provider network in exchange for a contractual based periodic fee.
Revenue is also generated from contracts with Clients for our chronic care management solutions. Substantially all of this revenue is derived from monthly access fees that are recognized as services are rendered and earned under subscription agreements with Clients that are based on a per-participant-per-month model, using the number of active enrolled members each month for the minimum enrollment period.
Revenue is also generated from contracts with Clients for our chronic care management solutions. Substantially all of this revenue is derived from monthly access fees that are recognized as services are rendered and earned under subscription agreements with Clients that are based on a PPPM model, using the number of active enrolled members each month for the minimum enrollment period.
Components of Results of Operations Cost of Revenue (exclusive of depreciation and amortization, which are shown separately) Cost of revenue (exclusive of depreciation and amortization, which are shown separately) primarily consists of fees paid to the physicians and other health professionals in our provider network; product cost; costs incurred in connection with our provider network operations and data center activities, which include employee-related expenses (including salaries and benefits, incentive compensation, and stock-based compensation); costs related to Client support; and provider network, medical records, magnetic resonance imaging, medical lab tests, translation, postage, medical malpractice insurance, and deferred device costs.
Components of Results of Operations Cost of Revenue (exclusive of depreciation and amortization, which are shown separately) Cost of revenue (exclusive of depreciation and amortization, which are shown separately), or "Cost of revenue," primarily consists of fees paid to the physicians and other health professionals in the THMG Association provider network; product cost; costs incurred in connection with the THMG Association provider network operations and data center activities, which include employee-related expenses (including salaries and benefits, incentive compensation, and stock-based compensation); costs related to Client support; and provider network, medical records, magnetic resonance imaging, medical lab tests, translation, postage, medical malpractice insurance, and deferred device costs.
The income tax provision for the year ended December 31, 2023 reflects the current year operational loss and the impact of lower stock-based compensation deductions for tax purposes compared to the stock-based compensation expense recorded in the consolidated statement of operations.
The income tax provision for the year ended December 31, 2024 reflects the current year operational loss and the impact of lower stock-based compensation deductions for tax purposes compared to the stock-based compensation expense recorded in the consolidated statement of operations.
We further believe that increasing our membership is an integral objective that will provide us with the ability to continually innovate our services and support initiatives that will enhance members’ experiences. U.S.
We further believe that increasing our membership is an integral objective that will provide us with the ability to continually innovate our services and support initiatives that will enhance members’ experiences.
We record access fees from Clients accessing our professional provider network or hosted virtual healthcare platform or chronic care management platforms, visit fee revenue for general medical, expert medical service and other specialty visits as well as other revenue primarily associated with virtual healthcare device equipment included with our hosted virtual healthcare platform.
We record access fees from Clients accessing the THMG Association professional provider network or hosted virtual healthcare platform or chronic care management platforms, visit fee revenue for general medical, expert medical service and other specialty visits as well as other revenue primarily associated with virtual healthcare device equipment included with our hosted virtual healthcare platform.
Integrated Care Segment As it relates to the Integrated Care segment, we primarily generate virtual healthcare service revenue from contracts with Clients who purchase access to our professional provider network or medical experts for their employees, dependents and other beneficiaries.
Integrated Care Segment As it relates to the Integrated Care segment, we primarily generate virtual healthcare service revenue from contracts with Clients who purchase access to the THMG Association professional provider network or medical experts for their employees, dependents and other beneficiaries.
These solutions integrate devices, supplies, access to our web-based platform, and clinical and data services to provide an overall health management solution.
These solutions integrate devices, supplies, access to our web-based platform, mobile application, and clinical and data services to provide an overall health management solution.
Integrated Care Member . Average monthly revenue per U.S. Integrated Care member measures the average monthly amount of global revenue that we generate from a U.S. Integrated Care member for a particular period. It is calculated by dividing the total revenue generated from the Integrated Care segment by the average number of U.S. Integrated Care members during the applicable period.
Average Monthly Revenue Per U.S. Integrated Care Member . Average monthly revenue per U.S. Integrated Care member measures the average monthly amount of global revenue that we generate from a U.S. Integrated Care member for a particular period. It is calculated by dividing the total revenue generated from the Integrated Care segment by the average number of U.S.
As a result of this dynamic, we have typically experienced fewer new member additions and the strongest operating income performance in the fourth quarter. Conversely, as marketing activity typically resumes at the start of the year, we typically experience the weakest operating income performance during the first quarter as new customer acquisition and revenue growth lags marketing spend.
As a result of this dynamic, we have typically experienced fewer new member additions and strong operating income performance in the fourth quarter. Conversely, as marketing activity typically resumes at the start of the year, we typically experience weak operating income performance during the first quarter as new customer acquisition and revenue growth lags marketing spend.
Interest and penalties, if any, related to accrued liabilities for potential tax assessments are included in income tax expense. Valuation allowances are recorded to reduce deferred tax assets when it is more likely than not that a tax benefit will not be realized.
Interest and penalties, if any, related to accrued liabilities for potential tax assessments are included in income tax expense. 60 Table of Contents Valuation allowances are recorded to reduce deferred tax assets when it is more likely than not that a tax benefit will not be realized.
Determination of valuation allowances recorded against deferred tax assets requires significant 58 Table of Contents judgment and use of assumptions, including past operating results, estimates of future taxable income and the feasibility of tax planning strategies.
Determination of valuation allowances recorded against deferred tax assets requires significant judgment and use of assumptions, including past operating results, estimates of future taxable income and the feasibility of tax planning strategies.
Our future capital requirements will depend on many factors including our growth rate, contract renewal activity, number of visits, the timing and extent of spending to support product development efforts, our expansion of sales and marketing activities, the introduction of new and enhanced services offerings, the continuing market acceptance of telehealth, and our debt service obligations.
Our future capital requirements will depend on many factors including our growth rate, contract renewal activity, number of visits, our ability to retain and/or obtain new members, the timing and extent of spending to support product development efforts, our expansion of sales and marketing activities, the introduction of new and enhanced services offerings, the continuing market acceptance of telehealth, and our debt service obligations.
Management’s Discussion and Analysis of Financial Condition and Results of Operations Discussion and analysis of our fiscal year 2021, as well as the year-over-year comparison of our 2022 financial performance to 2021, have been omitted from this section and may be found under the heading “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2022 that was filed with the SEC on March 1, 2023.
Management’s Discussion and Analysis of Financial Condition and Results of Operations Discussion and analysis of our fiscal year 2022, as well as the year-over-year comparison of our 2023 financial performance to 2022, have been omitted from this section and may be found under the heading “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2023 that was filed with the SEC on February 23, 2024.
These transformation cost adjustments made to our results do not represent normal, recurring, operating expenses necessary to operate the business but rather, incremental costs incurred in connection with our acquisition and integration activities; and • Adjusted EBITDA does not reflect the significant non-cash stock-based compensation expense which should be viewed as a component of recurring operating costs.
These transformation cost adjustments made to our results do not represent normal, recurring, operating expenses necessary to operate the business but rather, incremental costs incurred in connection with our acquisition and integration activities; • Adjusted EBITDA does not reflect goodwill impairment charges; and 63 Table of Contents • Adjusted EBITDA does not reflect the significant non-cash stock-based compensation expense which should be viewed as a component of recurring operating costs.
Our Client contracts include a per-member-per-month (“PMPM”) access fee as well as certain contracts that also include additional revenue on a per-virtual healthcare visit basis for general medical, or other specialty visits or expert medical service on a per case basis.
Our Client contracts include a PMPM access fee as well as certain contracts that also include additional revenue on a per-virtual healthcare visit basis for general medical, or other specialty visits or expert medical service on a per case basis.
For example, a sustained increase in the customer attrition rate related to customers acquired in the Livongo transaction could prompt us to reduce our estimate of the remaining useful life of the customer relationships. Should this occur, a one-year reduction to the estimated life would result in an annual increase in amortization expense of approximately $6 million.
For example, a sustained increase in the customer attrition rate related to customers added as a result of the Livongo acquisition could prompt us to reduce our estimate of the remaining useful life of the customer relationships. Should this occur, a one-year reduction to the estimated life would result in an annual increase in amortization expense of approximately $6.0 million.
For additional revenue, deferred revenue, deferred costs, and disclosures, refer to Note 3. “Revenue, Deferred Revenue, and Deferred Costs and Other.” BetterHelp Segment As it relates to the BetterHelp segment, users can purchase virtual therapy services for an access fee, generally on a monthly basis.
For additional revenue, deferred revenue, deferred costs, and disclosures, refer to Note 3. “Revenue, Deferred Revenue, and Deferred Device and Contract Costs.” BetterHelp Segment As it relates to the BetterHelp segment, users can purchase virtual therapy services for an access fee, generally on a monthly or weekly basis.
We estimate the expected amount of refunds to be issued based on historical experience, which are recorded as a reduction of revenue. We issued refunds of approximately $93.0 million and $79.2 million for the years ended December 31, 2023 and 2022, respectively.
We estimate the expected amount of refunds to be issued based on historical experience, which are recorded as a reduction of revenue. We issued refunds of approximately $84.0 million and $93.0 million for the years ended December 31, 2024 and 2023, respectively.
The current estimated cost of these contracts is not expected to be significant to our liquidity and capital resources based on contracts in place as of December 31, 2023. Cash from Operating Activities Cash flows provided by operating activities consist of net loss adjusted for certain non-cash items and the cash effect of changes in assets and liabilities.
The current estimated cost of these contracts is not expected to be significant to our liquidity and capital resources based on contracts in place as of December 31, 2024. 68 Table of Contents Cash from Operating Activities Cash flows provided by operating activities consisted of net loss adjusted for certain non-cash items and the cash effect of changes in assets and liabilities.
For the years ended December 31, 2023 and 2022, revenue recognized from performance obligations related to prior periods for changes in estimated transaction price or Client performance guarantees was $14.7 million and $4.4 million, respectively.
For the years ended December 31, 2024 and 2023, revenue recognized from performance obligations related to prior periods for changes in estimated transaction price or Client performance guarantees was $5.9 million and $14.7 million, respectively.
It also includes costs related to certain business transformation initiatives focused 61 Table of Contents on integrating and optimizing various operations and systems, including upgrading our CRM and ERP systems.
It also includes costs related to certain business transformation initiatives focused on integrating and optimizing various operations and systems, including upgrading our CRM and ERP systems.
Cost of revenue (exclusive of depreciation and amortization, which are shown separately) is driven primarily by the number of general medical visits, expert medical services, and other specialty visits completed in each period and are closely correlated or directly related to delivery of our solutions and monthly access fees.
Cost of revenue is driven primarily by the number of general medical visits, expert medical services, and other specialty visits completed in each period and are closely correlated or directly related to delivery of our solutions and monthly access fees.
Cash provided by operating activities for the years ended December 31, 2023 and 2022 included approximately $15.6 million and $19.1 million, respectively, related to investments in and implementation of cloud computing applications, which are deferred and amortized over multiple years based on the expected contract life.
Cash provided by operating activities for the years ended December 31, 2024 and 2023 included approximately $3.7 million and $15.6 million, respectively, of payments made related to investments in and implementation of cloud computing applications, which are deferred and amortized over multiple years based on the expected contract life.
During 2023, we experienced positive operating cash flow and we anticipate increasing positive operating cash flow results for 2024. We believe that our existing cash and cash equivalents will be sufficient to meet our working capital, capital expenditure, and contractual obligation needs for at least the next 12 months.
During 2024, we experienced positive operating cash flow and we also anticipate continuing positive operating cash flows for 2025. We believe that our existing cash and cash equivalents will be sufficient to meet our working capital, capital expenditure, and contractual obligation needs for at least the next 12 months.
Some of these limitations are: • EBITDA and Adjusted EBITDA eliminate the impact of the provision for income taxes on our results of operations, and they do not reflect goodwill impairment, interest income, interest expense or other (income) expense, net; • Adjusted EBITDA does not reflect restructuring costs.
Some of these limitations are: • Adjusted EBITDA eliminates the impact of the provision for income taxes on our results of operations, and does not reflect other expense (income), net, interest income, or interest expense; • Adjusted EBITDA does not reflect restructuring costs.
Item 6. [Reserved] Not applicable. 53 Table of Contents Item 7.
Item 6. [Reserved] Not applicable. 55 Table of Contents Item 7.
In addition, although depreciation and amortization are non-cash charges, the assets being depreciated and amortized will often have to be replaced in the future, and both EBITDA and Adjusted EBITDA do not reflect any expenditures for such replacements.
In addition, although amortization of intangible assets and depreciation of property and equipment are non-cash charges, the assets being amortized and depreciated will often have to be replaced in the future, and Adjusted EBITDA does not reflect any expenditures for such replacements.
Many of the elements of the cost of revenue (exclusive of depreciation and amortization, which are shown separately) are relatively variable, and can be reduced in the near-term to offset any decline in our revenue. Our business and operational models are designed to be highly scalable and leverage variable costs to support revenue-generating activities.
Many of the elements of the cost of revenue are relatively variable, and can be reduced in the near-term to offset any decline in our revenue. Our business and operational models are designed to be highly scalable and leverage variable costs to support revenue-generating activities. Cost of revenue does not include an allocation of depreciation and amortization.
Cash provided by financing activities for the year ended December 31, 2022 was $6.5 million and primarily consisted of $5.9 million of proceeds from the exercise of employee stock options and $6.5 million of proceeds from participants in our employee stock purchase plan.
Cash from Financing Activities Cash provided by financing activities for the year ended December 31, 2024 was $8.3 million and primarily consisted of $3.6 million of proceeds from the exercise of employee stock options and $4.7 million of proceeds from participants in our employee stock purchase plan.
Adjusted EBITDA consists of net loss before interest income; interest expense; other (income) expense, net, including foreign currency exchange gains or losses; provision for income taxes; depreciation; amortization; goodwill impairment; stock-based compensation; restructuring costs; and acquisition, integration, and transformation costs. Free cash flow is net cash provided by operating activities less capital expenditures and capitalized software development costs.
Adjusted EBITDA consists of net loss before provision for income taxes; other expense (income), net; interest income; interest expense; depreciation of property and equipment; amortization of intangible assets; restructuring costs; acquisition, integration, and transformation cost; goodwill impairment; and stock-based compensation. Free cash flow is net cash provided by operating activities less capital expenditures and capitalized software development costs.
It also includes costs related to certain business transformation initiatives focused on integrating and optimizing various operations and systems, including upgrading our CRM and ERP systems, incurred in connection with our acquisition and integration activities.
It also includes costs related to certain business transformation initiatives focused on integrating and optimizing various operations and systems, including upgrading our CRM and ERP systems, incurred in connection with our acquisition and integration activities. Amortization of Intangible Assets Amortization of intangible assets consists of the amortization of capitalized software development costs and of acquisition-related intangible assets.
Our contracts do not generally contain refund provisions for fees earned related to services performed. 56 Table of Contents Additionally, certain of our contracts include Client performance guarantees and pricing adjustments that are based upon minimum member utilization and guarantees by us for specific service level performance, member satisfaction scores, cost savings or other value achievements or guarantees, and health outcome guarantees.
Additionally, certain of our contracts include Client performance guarantees and pricing adjustments that are based upon minimum member utilization and guarantees by us for specific service level performance, member satisfaction 58 Table of Contents scores, cost savings or other value achievements or guarantees, and health outcome guarantees.
Average monthly revenue per U.S. Integrated Care member decreased to $1.41 in the year ended December 31, 2023, from $1.42 in the same period in 2022, primarily due to the impact of new members onboarded over the course of the year.
Integrated Care member decreased to $1.37 in the year ended December 31, 2024, from $1.41 in the same period in 2023, primarily due to the impact of new members onboarded over the course of the year.
We recorded an income tax expense of $0.8 million for the year ended December 31, 2023, compared to an income tax benefit of $3.8 million for the year ended December 31, 2022.
We recorded income tax expense of $7.6 million for the year ended December 31, 2024, compared to $0.8 million for the year ended December 31, 2023.
Total revenue was $2,602.4 million for the year ended December 31, 2023, compared to $2,406.8 million for the year ended December 31, 2022, an increase of $195.6 million, or 8%. The increase was driven by an 8% increase in access fees, primarily related to BetterHelp, as well as a 6% increase in other revenues.
Total revenue was $2,569.6 million for the year ended December 31, 2024, compared to $2,602.4 million for the year ended December 31, 2023, a decrease of $32.8 million, or 1%. The decrease was driven by a 3% decrease in access fees, primarily related to BetterHelp, offset by an 11% increase in other revenues.
Integrated Care members increased by 6.3 million, or 8%, to 89.6 million at December 31, 2023, compared to the same period in 2022. 54 Table of Contents Chronic Care Program Enrollment . Chronic care program enrollment represents the total number of enrollees across our suite of chronic care programs at the end of a given period.
U.S. Integrated Care members increased by 4.2 million, or 5%, to 93.8 million at December 31, 2024, compared to the same period in 2023. Chronic Care Program Enrollment . Chronic care program enrollment represents the total number of enrollees across our suite of chronic care programs at the end of a given period.
Our chronic care program enrollments are one of the key components of our whole person virtual care platform that we believe positions us to drive greater engagement with our platforms and increased revenue. Chronic care program enrollment increased by 14% to 1.16 million at December 31, 2023, compared to 1.02 million at December 31, 2022. Average Monthly Revenue Per U.S.
Our chronic care program enrollments are one of the key components of our virtual care platform that we believe positions us to drive greater engagement with our platforms 56 Table of Contents and increased revenue. Chronic care program enrollment increased by 4% to 1.20 million at December 31, 2024, compared to 1.16 million at December 31, 2023.
In connection with the brand strategy, we accelerated the amortization associated with the Livongo trademark, increasing amortization expense in the year ended December 31, 2023 and in the year ending December 31, 2024, with corresponding reductions thereafter.
In connection with the brand strategy,we accelerated the amortization of intangible assets that are associated with the Livongo trademark, increasing amortization of intangible assets expense beginning in the second half of 2023 and continuing through the year ended December 31, 2024 , with corresponding reductions thereafter.
Restructuring Costs Restructuring costs consist primarily of lease impairment costs, losses related to the reduction of office space, and costs for employee transition, severance payments, employee benefits, and related costs. Depreciation Depreciation consists primarily of depreciation of fixed assets. Amortization Amortization consists primarily of amortization of capitalized software development costs, and amortization of acquisition-related intangible assets.
Restructuring Costs Restructuring costs consist primarily of lease impairment costs, losses related to the reduction of office space, and costs for employee transition, severance payments, employee benefits, and related costs.
We believe that our ability to add new paying users and retain existing users is a key indicator of the increasing market adoption of BetterHelp, the growth of that business, and future revenue potential.
We believe that our ability to add new paying users and retain existing users is a key indicator of the market adoption of BetterHelp, the growth of this segment, and future revenue potential. Effectively reaching potential paying users through various advertising channels remains critical to our success.
Cash used in investing activities for the year ended December 31, 2022 of $167.7 million consisted primarily of capitalized software development costs of $156.3 million and capital expenditures of $16.5 million. The decrease of $11.4 million related to lower capitalized software development costs.
Cash used in investing activities for the year ended December 31, 2023 of $156.3 million, and consisted primarily of capitalized software development costs of $144.9 million and capital expenditures of $11.5 million. The decrease of $32.3 million was primarily driven by lower capitalized software development costs.
The primary uses of cash from operating activities are for the payment of cash compensation, provider fees, engagement marketing, direct-to-consumer digital and media advertising, inventory, insurance, technology costs, interest expense and acquisition, integration, and transformation costs.
The primary uses of cash from operating activities are for the payment of cash compensation, provider fees, engagement marketing, direct-to-consumer digital and media advertising, inventory, insurance, technology costs, interest expense and acquisition, integration, and transformation costs. Historically, cash compensation is at its highest level in the first quarter when discretionary employee compensation related to the previous fiscal year is paid.
Unless the context otherwise requires, Teladoc Health, Inc., together with its subsidiaries, is referred to herein as “Teladoc Health,” the “Company,” or “we.” The Company’s principal executive office is located in Purchase, New York.
Unless the context otherwise requires, Teladoc Health, Inc., together with its subsidiaries, is referred to herein as “Teladoc Health,” the “Company,” or “we.” The Company’s principal executive office is located in Purchase, New York. Teladoc Health is the global leader in virtual care focused on forging a new healthcare experience with better convenience, outcomes, and value around the world.
Restructuring costs were $16.9 million and $7.4 million for the year ended December 31, 2023 and 2022, respectively. The costs primarily consisted of losses related to the reduction of office space and severance. See Note 12. ‘Restructuring” to the financial statements for additional information. Depreciation.
Restructuring Costs . Restructuring costs were $20.4 million and $16.9 million for the years ended December 31, 2024 and 2023, respectively. The costs primarily related to the reduction of office space, severance, right-of-use asset impairment charges and other restructuring related costs. See Note 12. ‘Restructuring” to the financial statements for additional information. Amortization of Intangible Assets.
Other (income) expense, net was an income of $4.4 million for the year ended December 31, 2023, compared to an expense of $0.9 million for the year ended December 31, 2022, primarily reflecting a gain on the partial sale of a business. Provision for Income Taxes .
Other expense (income), net was an expense of $6.0 million for the year ended December 31, 2024, compared to an income of $4.4 million for the year ended December 31, 2023, primarily reflecting losses on foreign currency exchange rate fluctuations for the year ended December 31, 2024, whereas the year ended December 31, 2023 reflected a gain on the partial sale of a business, partially offset by losses on foreign currency exchange rate fluctuations. 66 Table of Contents Provision for Income Taxes .
In connection with the brand strategy, we have accelerated the amortization associated with the Livongo trademark, increasing amortization expense in the year ended December 31, 2023 , and in the year ending December 31, 2024, with corresponding reductions thereafter.
In connection with the brand strategy, we accelerated the amortization of intangible assets that are associated with the Livongo trademark, increasing amortization of intangible assets expense beginning in the second half of the year ended December 31, 2023 and continuing through the year ended December 31, 2024 , with corresponding reductions thereafter. Depreciation of Property and Equipment.
The following table shows amortization broken down by components for the periods indicated (in thousands): Year Ended December 31, 2023 2022 % Amortization of acquired intangibles $ 242,976 $ 198,522 22 % Amortization of capitalized software 82,957 46,098 80 % Amortization of intangible assets expense $ 325,933 $ 244,620 33 % Amortization was $325.9 million for the year ended December 31, 2023, compared to $244.6 million for the year ended December 31, 2022, an increase of $81.3 million, or 33%.
The following table shows amortization of intangible assets broken down by components for the periods indicated (in thousands): Year Ended December 31, 2024 2023 % Amortization of acquired intangibles $ 230,328 $ 242,976 (5) % Amortization of capitalized software development costs 133,037 82,957 60 % Amortization of intangible assets expense $ 363,365 $ 325,933 11 % Amortization of intangible assets was $363.4 million for the year ended December 31, 2024, compared to $325.9 million for the year ended December 31, 2023, an increase of $37.4 million, or 11%.
The year-over-year increase was substantially driven by growth in operating cash flow, and to a lesser degree, a decline in capitalized expenditures and capitalized software.
The year-over-year decrease was substantially driven by a decline in operating cash flow, partially offset by a decline in capitalized software.
The following is a reconciliation of net cash provided by operating activities to free cash flow (in thousands, unaudited): Year Ended December 31, 2023 2022 2021 Net cash provided by operating activities $ 350,021 $ 189,292 $ 193,990 Capital expenditures (11,464) (16,480) (8,534) Capitalized software (144,884) (156,284) (55,400) Free Cash Flow $ 193,673 $ 16,528 $ 130,056 Free cash flow was $193.7 million for the year ended December 31, 2023, as compared to $16.5 million for the year ended December 31, 2022.
The following is a reconciliation of net cash provided by operating activities to free cash flow (in thousands, unaudited): Year Ended December 31, 2024 2023 Net cash provided by operating activities $ 293,680 $ 350,021 Capital expenditures (10,790) (11,464) Capitalized software development costs (113,262) (144,884) Free Cash Flow $ 169,628 $ 193,673 Free cash flow was $169.6 million for the year ended December 31, 2024, as compared to $193.7 million for the year ended December 31, 2023.
The higher expense was driven by higher amortization due to the acceleration of certain trademark lives as well as an increase in the amortization of capitalized software costs related to our investment in platforms.
The higher expense was driven by an increase in the amortization of capitalized software development costs related to our investment in platforms, partially offset by lower amortization of acquired intangibles due to certain trademarks becoming fully amortized.
“Intangible Assets, Net and Certain Cloud Computing Costs” to the 57 Table of Contents consolidated financial statements. We also review the useful lives on a quarterly basis to determine if the period of economic benefit has changed.
We also review the useful lives on a quarterly basis to determine if the period of economic benefit has changed.
Depreciation was $11.1 million for the year ended December 31, 2023, compared to $11.4 million for the year ended December 31, 2022, a decrease of $0.3 million, or 2%. Amortization.
Depreciation of property and equipment was $10.2 million for the year ended December 31, 2024, compared to $11.1 million for the year ended December 31, 2023, a decrease of $1.0 million, or 9%. Interest Income. Interest income was $57.1 million for the year ended December 31, 2024, compared to $46.8 million for the year ended December 31, 2023.
Sales expenses were $213.8 million for the year ended December 31, 2023, compared to $227.2 million for the year ended December 31, 2022, a decrease of $13.4 million, or 6%. The decrease was primarily driven by lower employee compensation as well as lower sales and broker commissions. Technology and Development Expenses.
The decrease was primarily driven by lower employee compensation, partially offset by higher professional fees and broker commissions. Technology and Development Expenses. Technology and development expenses were $307.3 million for the year ended December 31, 2024, compared to $348.5 million for the year ended December 31, 2023, a decrease of $41.2 million, or 12%.
In evaluating these financial measures, you should be aware that in the future we may incur expenses similar to those eliminated in this presentation.
In evaluating these financial measures, you should be aware that in the future we may incur expenses similar to those eliminated in this presentation. Our presentation of these non-GAAP measures should not be construed as an inference that our future results will be unaffected by unusual or nonrecurring items.
The increase in other revenues primarily related to higher revenues from sales of our telehealth solutions for hospitals and health systems. By geography, total revenue for the U.S. was $2,237.5 million and for International was $364.9 million for the year ended December 31, 2023, reflecting increases of 6% and 19%, respectively, compared to the year ended December 31, 2022.
The increase in other revenues primarily related to higher visit revenues. By geography, total revenue for the U.S. was $2,160.0 million and for International was $409.6 million for the year ended December 31, 2024, reflecting a decrease of 3% and an increase of 12%, respectively, compared to the year ended December 31, 2023.
Approximately 20% of total Integrated Care revenues relates to international and hospital and health systems for which membership is not considered as a management metric. We believe that our ability to increase the revenue generated from each member over time is also a key indicator of our increasing market adoption, the growth of our business, and future revenue potential.
We believe that our ability to increase the revenue generated from each member over time is also a key indicator of our increasing market adoption, the growth of our business, and future revenue potential. Average monthly revenue per U.S.
BetterHelp Adjusted EBITDA increased by $22.1 million, or 19%, to $136.2 million for the year ended December 31, 2023, primarily reflecting higher gross profit, offset by higher operating expenses, most significantly higher advertising and marketing expenses. 66 Table of Contents Liquidity and Capital Resources The following table presents a summary of our cash flow activity for the years ended December 31, 2023 and 2022 (in thousands): Year Ended December 31, Consolidated Statements of Cash Flows - Summary 2023 2022 Net cash provided by operating activities $ 350,021 $ 189,292 Net cash used in investing activities (156,347) (167,743) Net cash provided by financing activities 10,854 6,497 Effect of foreign currency exchange rate changes 965 (3,344) Total increase in cash and cash equivalents $ 205,493 $ 24,702 Our principal sources of liquidity are cash and cash equivalents, totaling $1,123.7 million as of December 31, 2023.
Liquidity and Capital Resources The following table presents a summary of our cash flow activity for the years ended December 31, 2024 and 2023 (in thousands): Year Ended December 31, Consolidated Statements of Cash Flows - Summary 2024 2023 Net cash provided by operating activities $ 293,680 $ 350,021 Net cash used in investing activities (124,052) (156,347) Net cash provided by financing activities 8,312 10,854 Effect of foreign currency exchange rate changes (3,288) 965 Total increase in cash and cash equivalents $ 174,652 $ 205,493 Our principal source of liquidity is our cash and cash equivalents, totaling $1,298.3 million as of December 31, 2024.
Teladoc Health is the global leader in whole person virtual care focused on forging a new healthcare experience with better convenience, outcomes, and value around the world. We were founded on a simple, yet revolutionary idea: that everyone should have access to the best healthcare, anywhere in the world on their terms.
We were founded on a simple, yet revolutionary idea: that everyone should have access to the best healthcare, anywhere in the world on their terms.
Our ability to reach new potential paying users through various advertising channels helped us to increase BetterHelp paying users by 9% to 0.46 million as of December 31, 2023, compared to 0.42 million as of December 31, 2022. As it relates to the Company: Seasonality. Our business has historically been subject to seasonality.
BetterHelp paying users decreased by 11% to 0.41 million for the year ended December 31, 2024, compared to 0.46 million for the year ended December 31, 2023. As it relates to the Company: Seasonality. Our business has historically been subject to seasonality.
These steps are expected to result in restructuring costs in the year ending December 31, 2024. See Note 19. ‘Subsequent Events” to the consolidated financial statements for additional information. Key Factors Affecting Our Performance We believe that our future performance will depend on many factors, including the following: As it relates to the Integrated Care segment: Number of U.S.
Key Factors Affecting Our Performance We believe that our future performance will depend on many factors, including the following: As it relates to the Integrated Care segment: Number of U.S. Integrated Care Members. U.S.
The increase was primarily driven by higher infrastructure, hosting, and software license costs associated with running operations and ongoing projects and services to continuously improve and optimize our products and services, partially offset by lower professional fees and contract labor costs and lower recruiting and employee-related costs.
The decrease was primarily driven by lower employee compensation costs, partially offset by higher infrastructure, hosting, and software license costs associated with running operations as well as ongoing projects and services to continuously improve and optimize our products and services. For the years ended December 31, 2024 and 2023, research and development costs were $89.1 million and $124.6 million, respectively.
“Convertible Senior Notes” to the consolidated financial statements for additional information on our convertible senior notes. We were in compliance with all debt covenants at December 31, 2023. We routinely enter into contractual obligations with third parties to provide professional services, licensing, and other products and services in support of our ongoing business.
We routinely enter into contractual obligations with third parties to provide professional services, licensing, and other products and services in support of our ongoing business.
Our presentation of these non-GAAP measures should not be construed as an inference that our future results will be unaffected by unusual or nonrecurring items. 62 Table of Contents Consolidated Results of Operations The following table sets forth our consolidated statement of operations data for the years ended December 31, 2023 and 2022 and the dollar and percentage change between the respective periods (dollars in thousands).
Consolidated Results of Operations The following table sets forth our consolidated statement of operations data for the years ended December 31, 2024 and 2023 and the dollar and percentage change between the respective periods (dollars in thousands, except per share data).
Other (Income) Expense, Net Other (income) expense, net includes the impact of foreign currency remeasurement, realized gains on investment securities, and all other non-operating items not included in other financial statement lines. Provision for Income Taxes Provision for income taxes reflects management’s best assessment of estimated current and future taxes to be paid.
Interest Expense Interest expense consists of interest costs and the amortization of debt discounts primarily associated with convertible senior notes. 62 Table of Contents Other Expense (Income), Net Other expense (income), net includes the impact of foreign currency remeasurement, realized gains on investment securities, and all other non-operating items not included in other financial statement lines.
Advertising and Marketing Expenses. Advertising and marketing expenses were $688.9 million for the year ended December 31, 2023, compared to $623.5 million for the year ended December 31, 2022, an increase of $65.3 million, or 10%. This increase was substantially driven by higher digital and media advertising costs related to BetterHelp. Sales Expenses.
The decrease was primarily driven by lower provider and technology costs, partially offset by higher amortization of device costs. Advertising and Marketing Expenses. Advertising and marketing expenses were $705.8 million for the year ended December 31, 2024, compared to $688.9 million for the year ended December 31, 2023, an increase of $16.9 million, or 2%.
For the 64 Table of Contents year ended December 31, 2023 and 2022, research and development costs were $124.6 million and $106.9 million, respectively. General and Administrative Expenses. General and administrative expenses were $464.7 million for the year ended December 31, 2023, compared to $449.9 million for the year ended December 31, 2022, an increase of $14.8 million, or 3%.
General and Administrative Expenses. General and administrative expenses were $435.5 million for the year ended December 31, 2024, compared to $464.7 million for the year ended December 31, 2023, a decrease of $29.2 million, 65 Table of Contents or 6%.
The increase in net revenues was primarily driven by higher chronic care program enrollment and adoption, as well as higher telemedicine product revenue, including higher revenues from our Primary360 offering.
Integrated Care total revenues increased by $60.1 million, or 4%, to $1,528.9 million for the year ended December 31, 2024. The increase in net revenues was primarily driven by higher chronic care program enrollment and adoption, as well as higher telemedicine product revenue.